BC Extra | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

Irene Chan has stepped down as deputy director of FDA's China office. She joined the office in 2009 as one of its first policy analysts, covering food safety. As deputy director, she worked closely with...
BC Extra | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
BC Extra | Jul 5, 2017
Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
BC Week In Review | Dec 1, 2016
Financial News

Essa Pharma completes debt financing

Essa drew down $8 million from a new $10 million term loan facility from Silicon Valley Bank. The loan bears interest at 3% plus the prime rate and matures on Sept. 1, 2020. The remaining...
BC Week In Review | Jan 18, 2016
Financial News

Essa Pharma completes private placement of units

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Business: Cancer   Date completed: 2016-01-14   Type: Private placement of units   Raised: $15 million   Units: 4.5 million   Price: $3.30 (unit)   Shares after...
BC Week In Review | Jan 11, 2016
Financial News

Essa Pharma proposes private placement of units

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Business: Cancer   Date announced: 2016-01-06   Type: Private placement of units   To be raised: About $15 million   Units: 4.5 million   Price: $3.30 (unit)...
BC Week In Review | Dec 7, 2015
Clinical News

EPI-506: Phase I/II started

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Product: EPI-506   Business: Cancer   Molecular target: Androgen receptor   Description: Selective blocker of the N-terminus of the androgen receptor   Indication: Treat metastatic castration-resistant prostate...
BC Week In Review | Mar 11, 2013
Company News

Vivus endocrine/metabolic news

Vivus investor First Manhattan Co. (FMC) said it plans to nominate a slate of six new directors to the biotech's board and urged Vivus to find a U.S. partner for obesity drug Qsymia phentermine/topiramate. In...
BC Extra | Mar 9, 2013
Company News

FMC wants new Vivus board, strategy

Vivus Inc. (NASDAQ:VVUS) investor First Manhattan Co. (FMC) said it plans to nominate a slate of six new directors to the biotech's board and urged Vivus to find a U.S. partner for obesity drug Qsymia...
BC Week In Review | Oct 17, 2011
Company News

Amgen, Epix autoimmune news

Amgen will sell the assets of the partners' sphingosine 1-phosphate receptor 1 ( S1PR1 ; S1P1 ; EDG1 ) agonists program in a sealed bid sale on Dec. 8. Amgen said the decision was based on its...
Items per page:
1 - 10 of 335
BC Extra | Oct 11, 2019
Company News

Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio

Irene Chan has stepped down as deputy director of FDA's China office. She joined the office in 2009 as one of its first policy analysts, covering food safety. As deputy director, she worked closely with...
BC Extra | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

John Johnson has resigned as CEO of Melinta Therapeutics Inc. (NASDAQ:MLNT). He will stay with the antibiotics company during the search for his successor. David Gill, a board member, was named chairman, replacing Kevin Ferro,...
BC Extra | Jul 5, 2017
Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
BC Week In Review | Dec 1, 2016
Financial News

Essa Pharma completes debt financing

Essa drew down $8 million from a new $10 million term loan facility from Silicon Valley Bank. The loan bears interest at 3% plus the prime rate and matures on Sept. 1, 2020. The remaining...
BC Week In Review | Jan 18, 2016
Financial News

Essa Pharma completes private placement of units

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Business: Cancer   Date completed: 2016-01-14   Type: Private placement of units   Raised: $15 million   Units: 4.5 million   Price: $3.30 (unit)   Shares after...
BC Week In Review | Jan 11, 2016
Financial News

Essa Pharma proposes private placement of units

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Business: Cancer   Date announced: 2016-01-06   Type: Private placement of units   To be raised: About $15 million   Units: 4.5 million   Price: $3.30 (unit)...
BC Week In Review | Dec 7, 2015
Clinical News

EPI-506: Phase I/II started

Essa Pharma Inc. (TSX:EPI; NASDAQ:EPIX), Vancouver, B.C.   Product: EPI-506   Business: Cancer   Molecular target: Androgen receptor   Description: Selective blocker of the N-terminus of the androgen receptor   Indication: Treat metastatic castration-resistant prostate...
BC Week In Review | Mar 11, 2013
Company News

Vivus endocrine/metabolic news

Vivus investor First Manhattan Co. (FMC) said it plans to nominate a slate of six new directors to the biotech's board and urged Vivus to find a U.S. partner for obesity drug Qsymia phentermine/topiramate. In...
BC Extra | Mar 9, 2013
Company News

FMC wants new Vivus board, strategy

Vivus Inc. (NASDAQ:VVUS) investor First Manhattan Co. (FMC) said it plans to nominate a slate of six new directors to the biotech's board and urged Vivus to find a U.S. partner for obesity drug Qsymia...
BC Week In Review | Oct 17, 2011
Company News

Amgen, Epix autoimmune news

Amgen will sell the assets of the partners' sphingosine 1-phosphate receptor 1 ( S1PR1 ; S1P1 ; EDG1 ) agonists program in a sealed bid sale on Dec. 8. Amgen said the decision was based on its...
Items per page:
1 - 10 of 335